secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2024-02-02T23:59:59+00:00
Accession:  0001104659-24-010057
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics reports preliminary cash balance of $21.6M as of Dec 31, 2023
--------------------------------------------------------------------------------

- Preliminary cash, cash equivalents, and restricted cash expected to be approximately $21.6 million as of December 31, 2023.
- Estimate is unaudited, preliminary, and subject to change upon completion of the year-end financial close process.
- Company has not yet completed its financial closing procedures; independent auditor has not reviewed the estimate.
- President and CEO Oren Gilad signed the filing; no further financial results or guidance provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465924010057/0001104659-24-010057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465924010057/tm244107d6_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-010057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer